Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000

Business Wire June 10, 2020

Appili Therapeutics Announces Filing of Prospectus Supplement and Proposed Concurrent Private Placement

Business Wire June 5, 2020

IIROC Trading Resumption - APLI

Canada NewsWire June 4, 2020

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

Business Wire June 4, 2020

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire June 3, 2020

IIROC Trading Halt - APLI

Canada NewsWire June 3, 2020

Health Canada Clears Appili Therapeutics' Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Business Wire May 21, 2020

IIROC Trading Resumption - APLI

Canada NewsWire May 11, 2020

IIROC Trading Halt - APLI

Canada NewsWire May 11, 2020

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical's Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities

Business Wire May 11, 2020

Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer

Business Wire April 21, 2020

Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020

Business Wire February 27, 2020

Appili Therapeutics Announces Closing of Public Offering of $10,250,000

Business Wire February 20, 2020

Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering

Business Wire February 14, 2020

IIROC Trading Resumption - APLI

Canada NewsWire February 13, 2020

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

Business Wire February 13, 2020

IIROC Trading Halt - APLI

Canada NewsWire February 12, 2020

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire February 12, 2020

Researchers Present Positive Interim Data on Appili Therapeutics' ATI-1701 Biodefense Program at 2020 ASM Biothreats

Business Wire January 28, 2020

Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors

Business Wire January 27, 2020